Acelarin (NUC-1031)
Biliary Tract Cancer, Ovarian Cancer
Phase 3Development status uncertain
Key Facts
Indication
Biliary Tract Cancer, Ovarian Cancer
Phase
Phase 3
Status
Development status uncertain
Company
About NuCana
NuCana is a UK-based, publicly traded biopharma company focused on transforming widely prescribed chemotherapy agents using its phosphoramidate-based ProTide technology. Its mission is to significantly improve survival outcomes for cancer patients by developing more effective and safer medicines. The company has a clinical-stage pipeline targeting various solid tumors and hematological malignancies, and is led by a management team with extensive drug development and commercialization expertise.
View full company profile